Skip to Content

Infinite Drug Diversity

New chemical-synthesis methods help researchers build more varied and complex drug candidates.

The genomics revolution has provided innumerable potential targets for new drugs. But many of these disease-causing proteins seem to be “undruggable”: companies can’t find compounds that inhibit them. Into this breach comes Boston startup Infinity Pharmaceuticals, which plans to use new chemical-synthesis methods to build more varied and complex drug candidates than have previously been possible.

Infinity’s technique, pioneered by Harvard University chemist and company cofounder Stuart Schreiber, involves binding simple starting compounds to hosts of small plastic supports. The compounds acquire new chemical groups as they are exposed to a series of carefully chosen solutions; the supports are separated at various steps, producing smaller collections bearing unique chemicals. Such reactions are easier to track than those performed in solution and can yield a wide variety of products.

Infinity’s pedigree is impressive. Richard Klausner, former head of the National Cancer Institute, and Eric Lander, the cofounder of genomics pioneer Millennium Pharmaceuticals, are scientific advisors. Steven Holtzman, Millennium’s longtime chief financial officer, says he left to become president and CEO of Infinity because “I felt that perfecting that biological revolution required a revolution in chemistryAnd I felt this platform had the best chance.”

Infinity is focusing first on drugs for diabetes, inflammation, cancer and bacterial infections. “At the very least, it will be a more diverse set of compounds to test,”says Brent Stockwell, a chemist at the Whitehead Institute for Biomedical Research in Cambridge, MA. “But perhaps they’ll even be better.” That would give drugmakers a cornucopia to rival the biologists’.

Keep Reading

Most Popular

Large language models can do jaw-dropping things. But nobody knows exactly why.

And that's a problem. Figuring it out is one of the biggest scientific puzzles of our time and a crucial step towards controlling more powerful future models.

OpenAI teases an amazing new generative video model called Sora

The firm is sharing Sora with a small group of safety testers but the rest of us will have to wait to learn more.

Google’s Gemini is now in everything. Here’s how you can try it out.

Gmail, Docs, and more will now come with Gemini baked in. But Europeans will have to wait before they can download the app.

This baby with a head camera helped teach an AI how kids learn language

A neural network trained on the experiences of a single young child managed to learn one of the core components of language: how to match words to the objects they represent.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.